// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1151 Abstracts

SURVIVAL IN SYSTEMIC SCLEROSIS RELATED PULMONARY ARTERIAL HYPERTENSION IN THE MODERN TREATMENT ERA: RESULTS FROM A MULTICENTRE AUSTRALIAN COHORT STUDY

K. Morrisroe - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Pulmonary arterial hypertension

Hydroxychloroquine

PREDICTORS OF RESPONSE TO METHOTREXATE IN PATIENTS WITH EOSINOPHILIC FASCIITIS

W.A. Sifuentes Giraldo - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Eosinophilic fasciitis

Hydroxychloroquine

MEASUREMENT OF SERUM ALPHA-KLOTHO IN SYSTEMIC SCLEROSIS PATIENTS: RESULTS FROM A PIVOTAL STUDY

R. Talotta - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Systemic inflammation

Hydroxychloroquine

SUBOPTIMAL VITAMIN D LEVELS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

C. Ramos - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

RECURRENT THROMBOSIS IN YOUNG PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME: THE RELEVANCE OF THE ANTIPHOSPHOLIPID ANTIBODY PROFILE

M. Rodrigues - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

HIP JOINT AVASCULAR NECROSIS IN A MULTI-ETHNIC SYSTEMIC LUPUS ERYTHEMATOSUS COHORT

S.S. Shaharir - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

APPLICATION OF NEW DEFINITIONS OF REMISSION IN SLE: DURABLE REMISSION IS RARE

T.R. Wilhelm - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

ADVERSE PREGNANCY OUTCOMES AND ASSOCIATED FACTORS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Z. Zhan - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

FACTORS DETERMINING HYDROXYCHLOROQUINE SERUM LEVELS IN A COHORT OF CHINESE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

C.C. Mok - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

PREDICTORS OF INCIDENT EPISODES OF PROTEINURIA AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

L.S. Magder - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

ADHERENCE TO VACCINATION AND OSTEOPOROSIS PREVENTION IN A FRENCH SYSTEMIC LUPUS ERYTHEMATOSUS COHORT

M. Scherlinger - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

BREASTFEEDING IN SYSTEMIC LUPUS ERITHEMATOSUS

M. Acevedo - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

INFLUENCES OF HYDROXYCHLOROQUINE USE ON THE RISK OF CANCERS IN PATIENTS WITH SJOGRE-S SYNDROME: PROPENSITY SCORE MATCHED LANDMARK ANALYSIS

T.T. Chuang - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Systemic inflammation

Hydroxychloroquine

SMOKING IS ASSOCIATED WITH FUTURE LUPUS CUTANEOUS ACTIVITY IN PROSPECTIVE ANALYSES

S.G. Kwatra - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cutaneous lupus erythematosus

Hydroxychloroquine

ANTI-PHOSPHOLIPID POSITIVITY IN HEALTHY SUBJECTS: EVALUATION OF RISK FOR THROMBOTIC EVENT AFTER A 5 YEARS FOLLOW-UP

F. Ceccarelli - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

DYSLIPIDEMIA AND ATHEROGENIC RISK IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

H.A. Radillo - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

DAMAGE INDEX IN PATIENTS WITH THROMBOTIC ANTIPHOSPHOLIPID SYNDROME: RETROSPECTIVE COHORT STUDY

L.A. Martinez-Martinez - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

ANTIPHOSPHOLIPID SYNDROME AND EPILEPSY: WHERE DO WE STAND?

M.A. Noureldine - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

CLINICAL, BIOLOGICAL AND IMMUNOLOGICAL FEATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS IN A GROUP OF TUNISIAN PATIENTS

T. Ben Salem - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

INCIDENCE AND RISK ANALYSIS OF OSTEOMYELITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: A NATIONWIDE COHORT STUDY

Y.F. Huang - European League Against Rheumatism (EULAR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Copyright © 2026. QuantiNova All rights reserved